Tandem Diabetes Care (TNDM) was given a new $45.00 price target by Rothschild & Co Redburn.
Tandem Diabetes Care (TNDM) had its "buy" rating reaffirmed by TD Cowen.
Tandem Diabetes Care (TNDM) had its price target lowered by The Goldman Sachs Group, Inc. from $28.00 to $25.00. They now have a "neutral" rating on the stock.
Assessing Tandem Diabetes Care (TNDM) Valuation After Recent Share Price Weakness [Yahoo! Finance]
Tandem Diabetes Care to Announce First Quarter 2026 Financial Results on May 7, 2026